SUMMARY Three cell lines, VM/Dk P497 P540 and P560 derived from the VM spontaneous murine astrocytoma have previously been fully characterised and found to differ in their degree of astrocytic differentiation. The in vitro chemosensitivity of the three lines has been investigated using the 35S-methionine uptake assay. Differential chemosensitivity was found to exist between the cell lines. The pattern of chemosensitivity in relation to astrocytic differentiation was complex but the least differentiated cell line, P497, tended to be the least chemosensitive. entiation. Cell line P560 contains 10 nm filaments in 98% of cells and shows a strong positive cytoplasmic reaction for GFAP in vitro and is considered the best differentiated of the three lines.6 The least differentiated cell line P497 contains 10 nm filaments in only 15% of cells and is only weakly positive when stained for GFAP in vitro. Cell line P540 is of intermediate differentiation.
Wilson and Bates' have proposed that the ideal brain tumour model for chemotherapy studies should be "a serially transplantable glioblastoma in the mouse". In addition Wilson2 has suggested that an ideal animal model for human glioma should be spontaneously arising, of glial origin, capable of intraparenchymal growth, uniformly fatal within a reasonable time period, capable of in vitro growth, transplantable both intracranially and subcutaneously in syngeneic animals and correlate with the therapeutic sensitivities of human gliomas. The choice of agents in current use for the chemotherapy of glioma has largely depended on results obtained from experimental models. Few, if any of these fulfil the criteria for an ideal therapeutic model of human glioma.
The inbred VM strain of mice has a high incidence of spontaneous astrocytomas.3 From one of these spontaneous murine astrocytomas (SMA) three permanent cell lines P497, P540 Table 3 Relative sensitivity of three VM/DK SMA derived sublines
Drug
Ranking* PCB P497 >tP560 > P540 VCR P560 > P540 = P497 CCNU P497 = P540 = P560 BCNU P497 > P540 = P560 VDS P497 = P560 > P540 ADM P560 = P497 = P540 C-PLAT P540 = P497 > P560 BLM P497 > P560 = P540 5-Fu P497 > P560 > P540 *Least to most sensitive tSignificant difference (p < 0-05) 1364 resistant tumour sublines, these agents can be shown to enter the cell but are then actively transported out. This results in a relatively low intracellular level of drug and thus to low cytotoxicity.21 22 A common cellular efflux process could explain cross-resistance between the two drugs. P540 is the least sensitive to only one drug, C-PLAT, but is considerably more sensitive than the other two cell lines to the vinca alkaloid VDS. An impressive collateral sensitivity for VDS has been reported in vivo in a subline of the Erhlich ascites tumour selected for resistance to C-PLAT. 23 The mechanism of this collateral sensitivity remains to be explained and indeed it was not found in one of the few other studies of these two drugs.
McMillan and coworkers24 reported cross-resistance between C-PLAT and VDS in a C-PLAT resistant murine mammary carcinoma. Clearly more data are required about these two drugs from different tumour systems before firm conclusions can be made, although some encouraging results have been obtained with a combination of VDS and C-PLAT in clinical chemotherapy.23
Little is known about differences in therapeutic sensitivities between human gliomas of different grades. Low grade gliomas are only rarely treated with chemotherapy and therefore clinical correlations are difficult. Indirect evidence from Burger and Vollmer25 suggests that high grade gliomas should be more responsive to adjuvant therapy. These authors estimated the cellularity of gliomas and correlated this with patient survival. They found a positive correlation between cellularity and survival in a group of patients treated with postoperative chemotherapy and radiotherapy. It 35 Although a number of animal brain tumour models have been developed for use in chemosensitivity studies26 none has been based upon a tumour which has arisen spontaneously. Of the animal models in use the 9L gliosarcoma in the rat is the only one to date which has been refined for both in vitro and in vivo chemotherapy studies.36 37 The tumour is biologically unstable, however, and whether its current sarcomatous nature detracts from clinical applications is unclear. The three cell lines derived from the VM/Dk spontaneous astrocytoma offer the potential for the development of an animal brain tumour model which fulfills many of the criteria of Wilson.2 In addition it allows the relationship between chemosensitivity and astrocytic differentiation to be explored both in vitro and in vivo. The present study forms the basis for further development of this model in which in vivo chemosensitivity of the three cell lines will be determined. Whether the in vitro pattern of differential sensitivity observed in this study will be reflected in the animal model remains to be seen.
